PMID- 27338538
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20191210
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
VI  - 203
IP  - 1
DP  - 2016 Jun 1
TI  - Human leukocyte antigen-DR13 and DR15 are associated with short-term lung 
      transplant outcomes.
PG  - 82-90
LID - S0022-4804(16)00135-9 [pii]
LID - 10.1016/j.jss.2016.03.041 [doi]
AB  - BACKGROUND: Lung transplantation outcomes are among the least favorable, with 
      most recipients eventually developing bronchiolitis obliterans syndrome (BOS) and 
      subsequent graft failure. The presence of human leukocyte antigen (HLA)-DR has 
      been implicated in the pathogenesis of BOS and may play a role in these poor 
      outcomes. METHODS: Lung transplant donor and recipient data were retrospectively 
      gathered from the United Network for Organ Sharing database from January 2006 to 
      June 2013. Donor and recipient characteristics, proportion of recipients treated 
      for first year rejection, and 5-y rates of survival and freedom from BOS were 
      determined according to HLA-DR1, -DR7, -DR13, and -DR15 status in both donor and 
      recipient. Each HLA-DR allele was stratified by donor-recipient pair positivity 
      status. RESULTS: A total of 7402 lung transplant recipients met the inclusion and 
      exclusion criteria. There were significant but small differences in donor and 
      recipient characteristics for each HLA-DR group. The recipients in the D(-)R(+) 
      pairing for HLA-DR13 and those in the D(+)R(-) pairing for HLA-DR15 had 
      significantly higher rates of receiving treatment for rejection within the first 
      year after transplant (P = 0.024 and P = 0.001, respectively). There were no 
      differences in 5-y survival or freedom from BOS for any of the four HLA-DR 
      alleles studied. CONCLUSIONS: There are higher rates of patients treated for 
      rejection within the first year who are either negative for the HLA-DR15 allele 
      but received a donor-positive lung or positive for the HLA-DR13 allele but 
      received a donor-negative lung for that allele. However, these differences do not 
      appear to affect long-term outcomes.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Gracon, Adam S A
AU  - Gracon AS
AD  - Department of Surgery, Indiana University School of Medicine, Indianapolis, 
      Indiana.
FAU - Liang, Tiffany W
AU  - Liang TW
AD  - Department of Surgery, Indiana University School of Medicine, Indianapolis, 
      Indiana.
FAU - Rothhaar, Katia
AU  - Rothhaar K
AD  - Department of Medicine, Division of Pulmonary and Critical Care, Indiana 
      University School of Medicine, Indianapolis, Indiana.
FAU - Wu, Jingwei
AU  - Wu J
AD  - Department of Biostatistics, Indiana University School of Medicine, Indianapolis, 
      Indiana.
FAU - Wilkes, David S
AU  - Wilkes DS
AD  - Department of Medicine, Division of Pulmonary and Critical Care, Indiana 
      University School of Medicine, Indianapolis, Indiana. Electronic address: 
      dsw4n@virginia.edu.
LA  - eng
GR  - R01 HL096845/HL/NHLBI NIH HHS/United States
GR  - R01 HL067177/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20160326
PL  - United States
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
RN  - 0 (Biomarkers)
RN  - 0 (HLA-DR Serological Subtypes)
RN  - 0 (HLA-DR13 antigen)
RN  - 0 (HLA-DR15 antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/metabolism
MH  - Bronchiolitis Obliterans/etiology/*immunology
MH  - Female
MH  - Graft Rejection/*immunology
MH  - HLA-DR Serological Subtypes/*metabolism
MH  - Humans
MH  - Logistic Models
MH  - *Lung Transplantation/mortality
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Postoperative Complications/*immunology
MH  - Retrospective Studies
MH  - Survival Analysis
OTO - NOTNLM
OT  - Antigen
OT  - Bronchiolitis obliterans syndrome
OT  - HLA-DR
OT  - Lung transplantation
OT  - Rejection
OT  - Type V collagen
EDAT- 2016/06/25 06:00
MHDA- 2017/06/22 06:00
CRDT- 2016/06/25 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/02/25 00:00 [revised]
PHST- 2016/03/18 00:00 [accepted]
PHST- 2016/06/25 06:00 [entrez]
PHST- 2016/06/25 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
AID - S0022-4804(16)00135-9 [pii]
AID - 10.1016/j.jss.2016.03.041 [doi]
PST - ppublish
SO  - J Surg Res. 2016 Jun 1;203(1):82-90. doi: 10.1016/j.jss.2016.03.041. Epub 2016 
      Mar 26.